Concurrent chemoradiotherapy (CRT) consisting of bolus cisplatin 100 mg/m 2 is a standard approach in locally advanced head and neck cancer (LAHNC). The addition of chemotherapy concomitant with ...

Head and neck cancers are among the most difficult to treat. They can be aggressive and are located near some of the body's ...

If you have head or neck cancer, your doctor will try to figure out how far it has advanced, or what stage it is in. They’ll also see if it has spread to other parts of your body.

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes in HPV-related oropharyngeal squamous cell carcinoma.

Jacobs, C, Makuch, R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of Head and Neck Contracts Program. J Clin Oncol 1990;8:838-847 Crossref ...

The combination of setanaxib and pembrolizumab improved survival outcomes in advanced head and neck cancer, according to topline data from a phase 2 study. Image: Adobe Stock.

Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 trial showed a ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials. ... in head and neck cancer in light of our ...

Eat a Healthy Diet: Base your diet on fruits, vegetables, and plant-based foods such as whole grains and beans. Choose ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) prolonged event-free survival (EFS), the ...